Replies to post #202081 on Biotech Values

[bladerunner1717]

>>PRTK

I think this will be a big drug. Trial had a SPA and FDA agreed this trial in enough for approval.

Peter,

I agree with you. In light of that, doesn't it seem to you that today's price action was extremely muted? There are some cash issues going forward, but a small raise should be able to take care of that. And that's assuming no partnerships are made in the meantime. Do you see PRTK as a buy here?


Bladerunner

[RockRat]

PRTK: don't follow this company, so quickly looked at a Zack's writeup that said they'd submit an NDA in early 2018. Apparently waiting for CAPB data to come in, but why? Why couldn't they file on this ABSSSI data and get to market a year sooner, and file a sNDA for CAPB?

TIA & Regards, RockRat

[DewDiligence]

PRTK +36%/AH on phase-3 Omadacycline data in CAP:

http://finance.yahoo.com/news/paratek-announces-positive-phase-3-200100588.html